Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 164

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 16K
Chunk 164
---
Item 16K. Cybersecurity

The
Company’s cybersecurity strategy is designed to provide a comprehensive approach to securing cybersecurity risks across our technology
stack, governance framework, and human elements for our operations globally. Cybersecurity risk management is a critical component of
our broader risk management strategy. Our cybersecurity program is built on industry best practices and is designed to proactively identify,
assess, and mitigate cybersecurity risks, including threats associated with the use of all third-party service providers. Our cybersecurity
risk assessment framework categorizes risks based on their potential impact and severity, and the Company implements targeted risk treatment
plans to ensure robust protection and resilience.

Two
of the Company’s staff members oversee the prevention, detection, mitigation, and remediation of cybersecurity incidents. Both these
employees have extensive experience in risk management and compliance generally, and have been overseeing cybersecurity and IT management
at the Company since they joined Radiopharm. They are supported by Continental Resources Inc. The service provider has been engaged by
the Company since late 2022 to provide strategic IT advice and manage the Company’s IT systems and infrastructure. The service provider,
who has over 55 years of experience in securing IT in health and life sciences organizations, manages cybersecurity risks through a number
of measures including the development and implementation of cybersecurity policies and procedures, training and penetration testing and
systems monitoring. Our executive management team members regularly collaborate and receive reports from our managed IT and cybersecurity
service provider, enabling ongoing assessment and monitoring of the Company’s cyber risk profile and initiatives.

Our
Board of Directors entrusts its Audit & Risk Committee with overseeing Radiopharm’s cybersecurity risk management, including
ensuring that management has established processes to evaluate and manage cybersecurity risks.

In
fiscal year 2025, we didnot identifyany cybersecurity threats that have materially impacted or are likely to materially impact our business
strategy, operational results, or financial condition. However, despite our proactive measures, we cannot entirely eliminate cybersecurity
risks or guarantee that no undetected incidents have occurred.

PART III